» Articles » PMID: 20711499

PDE8 Regulates Rapid Teff Cell Adhesion and Proliferation Independent of ICER

Overview
Journal PLoS One
Date 2010 Aug 17
PMID 20711499
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Abolishing the inhibitory signal of intracellular cAMP by phosphodiesterases (PDEs) is a prerequisite for effector T (Teff) cell function. While PDE4 plays a prominent role, its control of cAMP levels in Teff cells is not exclusive. T cell activation has been shown to induce PDE8, a PDE isoform with 40- to 100-fold greater affinity for cAMP than PDE4. Thus, we postulated that PDE8 is an important regulator of Teff cell functions.

Methodology/principal Findings: We found that Teff cells express PDE8 in vivo. Inhibition of PDE8 by the PDE inhibitor dipyridamole (DP) activates cAMP signaling and suppresses two major integrins involved in Teff cell adhesion. Accordingly, DP as well as the novel PDE8-selective inhibitor PF-4957325-00 suppress firm attachment of Teff cells to endothelial cells. Analysis of downstream signaling shows that DP suppresses proliferation and cytokine expression of Teff cells from Crem-/- mice lacking the inducible cAMP early repressor (ICER). Importantly, endothelial cells also express PDE8. DP treatment decreases vascular adhesion molecule and chemokine expression, while upregulating the tight junction molecule claudin-5. In vivo, DP reduces CXCL12 gene expression as determined by in situ probing of the mouse microvasculature by cell-selective laser-capture microdissection.

Conclusion/significance: Collectively, our data identify PDE8 as a novel target for suppression of Teff cell functions, including adhesion to endothelial cells.

Citing Articles

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8).

Basole C, Nguyen R, Lamothe K, Billis P, Fujiwara M, Vang A Cells. 2022; 11(4).

PMID: 35203312 PMC: 8870644. DOI: 10.3390/cells11040660.


Clinical Implication of Phosphodiesterase-4-Inhibition.

Schick M, Schlegel N Int J Mol Sci. 2022; 23(3).

PMID: 35163131 PMC: 8835523. DOI: 10.3390/ijms23031209.


Neuroinflammation in Ischemic Stroke: Inhibition of cAMP-Specific Phosphodiesterases (PDEs) to the Rescue.

Ponsaerts L, Alders L, Schepers M, de Oliveira R, Prickaerts J, Vanmierlo T Biomedicines. 2021; 9(7).

PMID: 34206420 PMC: 8301462. DOI: 10.3390/biomedicines9070703.


Epigenetics in psoriasis: perspective of DNA methylation.

Luo Y, Qu K, Kuai L, Ru Y, Huang K, Yan X Mol Genet Genomics. 2021; 296(5):1027-1040.

PMID: 34137900 DOI: 10.1007/s00438-021-01804-y.


The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Epstein P, Basole C, Brocke S Front Cell Dev Biol. 2021; 9:636778.

PMID: 33937235 PMC: 8085600. DOI: 10.3389/fcell.2021.636778.


References
1.
Sullivan G, Lee D, Ross W, DiVietro J, Lappas C, Lawrence M . Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol. 2003; 75(1):127-34. DOI: 10.1189/jlb.0603300. View

2.
Giembycz M . Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br J Pharmacol. 2008; 155(3):288-90. PMC: 2567889. DOI: 10.1038/bjp.2008.297. View

3.
Ghosh S, Goldin E, Gordon F, Malchow H, Rask-Madsen J, Rutgeerts P . Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348(1):24-32. DOI: 10.1056/NEJMoa020732. View

4.
Peter D, Jin S, Conti M, Hatzelmann A, Zitt C . Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol. 2007; 178(8):4820-31. DOI: 10.4049/jimmunol.178.8.4820. View

5.
Lorenowicz M, Fernandez-Borja M, Hordijk P . cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol. 2007; 27(5):1014-22. DOI: 10.1161/ATVBAHA.106.132282. View